Fig 1: BAL therapy alleviates inflammation and kidney tubular injury. A. AKI stage in all the groups at the endpoint (n = 5 per group). B. H&E staining of kidney tissue at the endpoint (green arrows indicate the edematous and dilated tubules; higher magnification images are shown in the insets below; Bar = 200 µm; Magnification Bar = 50 µm). C. Masson's staining of kidney tissue at the endpoint (higher magnification images are shown in the insets below; Bar = 200 µm; Magnification Bar = 50 µm). D. TLR4 staining of kidney tissue at the endpoint (higher magnification images are shown in the insets below; Bar = 200 µm; Magnification Bar = 50 µm). E. NGAL staining of kidney tissue at the endpoint (higher magnification images are shown in the insets below; Bar = 200 µm; Magnification Bar = 50 µm). F. AKI-associated plasma protein assay at 72 h (NGAL, OPN, MIF, IP-10, clusterin, KIM-1, L-FABP, cystatin C, B2M, TTF3, and TIMP-1; p < 0.05, p < 0.01, p < 0.001; n = 5 per group). G. TEM observation of the kidney at the endpoint (yellow arrow indicates swelling mitochondria; red arrow indicates the brush border; higher magnification images are shown in the insets below; Bar = 2 µm; Magnification Bar = 500 nm).